Actively Recruiting
Led by University of Manitoba · Updated on 2026-03-09
340
Participants Needed
5
Research Sites
52 weeks
Total Duration
Researchers are evaluating whether adding the VIEWER virtual care platform to usual care can reduce emergency department visits and hospitalizations or improve the perceived safety of virtual care for patients with advanced Chronic Kidney Disease (CKD). This study focuses on patients at high risk during the vulnerable period before starting dialysis, aiming to improve communication between patients and healthcare providers through remote monitoring. The trial is a national, pragmatic, multicenter randomized controlled study conducted at five Canadian sites. The VIEWER platform includes a wireless blood pressure cuff, weight scale, oxygen saturation monitor, wearable motion tracker, and a tablet with a custom app guiding patients through daily self-assessments. Patients in the intervention group use these devices and complete weekly symptom surveys over 12 months or until they begin dialysis, in addition to receiving usual care. The control group receives usual care alone, which may be virtual or in person. Healthcare providers receive alerts for out-of-range measurements and communicate with patients through a secure portal, integrating this data into clinical decision-making. Participants will be monitored over 12 months or until dialysis starts, completing surveys on patient experience, quality of life, and usability at regular intervals. Researchers will track hospitalizations, emergency visits, mortality, dialysis initiation, adherence to monitoring, and provider and patient perspectives through focus groups. Data collected via the VIEWER platform and standard assessments will help evaluate the impact of this telemonitoring approach on health outcomes and care experience.
CONDITIONS
CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 12 months or until dialysis initiation
Participants randomized to the intervention group will be trained to use the VIEWER telemonitoring platform and guided through daily self-assessments with connected devices, while control participants continue usual care.
Daily self-assessments via app and weekly symptom surveys; routine clinic visits as usual care
Duration - Up to 12 months or until dialysis initiation
Participants are monitored for adverse outcomes such as hospitalization or emergency visits, with patient-reported experience and quality of life questionnaires completed at multiple timepoints.
Questionnaires at baseline, 3, 6, 9, and 12 months or until dialysis initiation
Duration - At 12 months or end of study
At the end of the trial, usability and perspectives on the intervention are assessed through surveys and focus groups or interviews.
Focus groups or interviews and usability survey
Total: 5 locations
1
St. Boniface Hospital
Winnipeg, Manitoba, Canada, R2H 2A6
Actively Recruiting
2
Chronic Disease Innovation Centre, Seven Oaks Hospital
Winnipeg, Manitoba, Canada, R2V 3M3
Actively Recruiting
3
Health Sciences Centre
Winnipeg, Manitoba, Canada, R3A 1R9
Actively Recruiting
4
London Health Sciences Centre
London, Ontario, Canada, N6A 5W9
Actively Recruiting
5
Scarborough Health Network - General Hospital
Scarborough Village, Ontario, Canada, M1P 2V5
Actively Recruiting
C
Claudio Rigatto, MD
Z
Zahra Solati, PhD
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Zahra Solati, Paul Komenda, Navdeep Tangri...
https://pubmed.ncbi.nlm.nih.gov/41058978